Skip to main content

Table 3 Patient characteristics of the study population in the third supplementary analysis

From: Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia

 Short interval (n = 71)Long interval (n = 71) 
Number or
mean (sd)
(%)Number or mean (sd)(%)SDif
Age 54.25 (9.84) 54.01 (8.42) 0.026
GenderFemale5(7)5(7)0
Male66(93)66(93) 
ResidencyNon-north43(61)42(59)0.029
North28(39)29(41) 
Tumor size≤ 5 cm32(45)32(45)0
> 5 cm39(55)39(55) 
Tumor differentiationPoorly/undifferentiated17(24)18(25)0.033
Well/moderately54(76)53(75) 
RT deliveryNon-IGRT55(77)57(80)0.069
IGRT16(23)14(20) 
Use of PETNo9(13)7(10)0.089
Yes62(87)64(90) 
Tumor locationCervical0
Non-cervical 
T-stageT1–T29(13)9(13)0
T3–T462(87)62(87) 
N-stageNegative10(14)10(14)0
Positive61(86)61(86) 
DrinkingNo10(14)8(11)0.085
Yes61(86)63(89) 
Betel nut chewingNo28(39)27(38)0.029
Yes43(61)44(62) 
SmokingNo15(21)13(18)0.071
Yes56(79)58(82) 
BMI 22.56 (2.73) 22.11 (2.80) 0.164
Number of LNs< 1516(23)19(27)0.098
≥ 1555(77)52(73) 
RT dose (Gy) 47.38 (3.93) 47.48 (3.82) 0.025
Patient volumeLow volume21(30)16(23)0.161
High volume50(70)55(77) 
Positive LN 0.48 (0.91) 0.44 (0.84) 0.048
  1. BMI body mass index, IGRT image-guided radiotherapy, LN lymph node, nCCRT neoadjuvant concurrent chemoradiotherapy, PET positron emission tomography, RT radiotherapy, sd standard deviation, SDif standardized difference
  2. Rounded
  3. The exact numbers were not reported because of a Health and Welfare Data Science Center (HWDC) database center policy to avoid numbers in single cells (≤ 2)